New York, USA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Wet-Age Related Macular Degeneration Market to Observe Stupendous Growth by 2032, Predicts DelveInsight | Key Players - AbbVie, Opthea, AffaMed Therapeutics, EyeBiotech, Novartis, Hoffmann-La Roche, Kyowa Kirin, Skyline Therapeutics The increasing number of diagnosed cases of wet AMD, the current therapies, and the launch of emerging therapies will drive the wet AMD market growth in the forecast period (2023–2032).

美国纽约，2024年1月31日（环球通讯社）--湿性年龄相关性黄斑变性市场将在2032年实现惊人增长，DelveInsight预测主要参与者-AbbVie、Opthea、AffaMed Therapeutics、EyeBiotech、Novartis、Hoffmann-La Roche、Kyowa Kirin、Skyline Therapeutics湿性AMD的诊断病例越来越多，目前的治疗方法，新兴疗法的推出将在预测期（2023-2032年）推动湿性AMD市场的增长。

DelveInsight’s Wet-Age Related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices, wet AMD emerging drugs, market share of individual therapies, and current and forecasted wet AMD market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

DelveInsight的湿性年龄相关性黄斑变性市场洞察报告包括对当前治疗实践，湿性AMD新兴药物，个体疗法的市场份额以及2019年至2032年当前和预测的湿性AMD市场规模的全面了解，细分为7MM[美国，欧盟4国（意大利，西班牙，法国和德国），英国和日本]。

Key Takeaways from the Wet-Age Related Macular Degeneration Market Report According to DelveInsight's analysis, the market size for wet AMD reached USD 8 billion in 2021 across the 7MM and is expected to grow with a significant CAGR by 2032.DelveInsight's analysis reveals that the overall diagnosed population of wet AMD in the 7MM was reported as ~4 million in 2021.

湿性年龄相关性黄斑变性市场报告的主要收获根据DelveInsight的分析，湿性AMD的市场规模在2021年达到80亿美元，预计到2032年将以显着的复合年增长率增长。DelveInsight的分析显示，2021年，湿性AMD在7MM的总诊断人口约为400万。

Within this, the diagnosed population of wet AMD patients in the United States specifically was identified to be 1.2 million in the same year.Prominent companies working in the domain of wet AMD, including EyePoint Pharmaceuticals, Inc., AbbVie, Caregen Co. Ltd., Exegenesis Bio, Shanghai Henlius Biotech, Skyline Therapeutics, 4D Molecular Therapeutics, Ocugenix Corporation, Adverum Biotechnologies, Inc., Ashvattha Therapeutics, Inc., AiViva BioPharma, Inc., Ocular Therapeutix, Inc., Clearside Biomedical, Inc., Hoffmann-La Roche, Kyowa Kirin, Inc., Opthea Limited, .

其中，同年美国确诊的湿性AMD患者人数为120万。在湿性AMD领域工作的知名公司，包括EyePoint Pharmaceuticals，Inc.，AbbVie，Caregen Co.Ltd.，Exegenesis Bio，Shanghai Henlius Biotech，Skyline Therapeutics，4D Molecular Therapeutics，Ocugenix Corporation，Adverum Biotechnologies，Inc.，Ashvattha Therapeutics，Inc.，Aiva BioPharma，Inc.，Ocular Therapeutix，Inc.，Clearside Biomedical，Inc.，Hoffmann-La Roche，Kyowa Kirin，Inc.，Opthea Limited公司。